Source: International Congress 2019 – Hot topics in noninvasive ventilation
Disease area: Airway diseases, Sleep and breathing disorders



Rating:

Share or cite this content

Citations should be made in the following way:
J. Bräunlich (Leipzig, Germany), H. Wirtz (Leipzig, Germany). Nasal high-Flow (NHF) improves ventilation in patients with interstitial lung disease (ILD). 3703

Member's Comments

No comment yet.

Related content which might interest you: Effects of a combination of pulmonary rehabilitation (PR) and non invasive ventilation (NIV) in patients with advanced interstitial lung disease (ILD) Source: Annual Congress 2009 - Noninvasive ventilation in chronic respiratory failure Year: 2009 Effects of pulmonary rehabilitation in patients with interstitial lung disease (ILD) Source: Annual Congress 2009 - New treatment and outcome measures for pulmonary rehabilitation Year: 2009 Safety of sputum induction (SI) in interstitial lung disease (ILD) Source: Annual Congress 2007 - Clinical aspects of interstitial lung disease Year: 2007 Pulmonary rehabilitation (PR) outcomes in chronic obstructive pulmonary disease (COPD) compared with interstitial lung disease (ILD) Source: Annual Congress 2011 - Pulmonary rehabilitation: looking at alternative approaches and alternative populations beyond COPD Year: 2011 Pulmonary rehabilitation (PR) exercise tolerance improvement: Differences between interstitial lung disease (ILD) and chronic obstructive pulmonary disease (COPD) Source: Annual Congress 2013 –Exercise, physiotherapy techniques and assessment in different chronic conditions Year: 2013 Influence of smoking habit on static lung compliance (Cst) in interstitial lung diseases (ILD) patients Source: Eur Respir J 2002; 20: Suppl. 38, 194s Year: 2002 Benefits of pulmonary rehabilitation (PR) in patients with chronic obstructive pulmonary disease (COPD) and interstitial lung disease (ILD) having the same dyspnoea severity Source: International Congress 2018 – What’s hot in rehabilitation in COPD and interstitial lung disease (ILD)? Year: 2018 Is it possible to predict the outcome of the whole lung lavage (WLL) in pulmonary alveolar proteinosis (PAP)? Source: International Congress 2015 – IIPs: orphan Year: 2015 Inhaled GM-CSF in pulmonary alveolar proteinosis (PAP) patient refractory to plasmapheresis combined with multiple whole lung lavages (WLL) Source: International Congress 2016 – Orphan diseases I Year: 2016 Endoscopic lung volume reduction (eLVR) with endobronchial valves (EBV) in patients with hypercapnic respiratory failure Source: International Congress 2015 – Bronchoscopic treatment of COPD and asthma: valves, coils, thermoplastics and something more Year: 2015 Noninvasive positive pressure ventilation in patients with acute exacerbation of idiopathic pulmonary fibrosis Source: Annual Congress 2006 - Pulmonary fibrosis: pathophysiology and therapeutic approaches Year: 2006 Changes of respiratory mechanics (RM) during exacerbations of chronic obstructive pulmonary disease (COPD) requiring noninvasive ventilation (NIV) Source: Annual Congress 2010 - News from noninvasive ventilation Year: 2010 Efficacy of non-invasive positive pressure ventilation (NIPPV) in cystic fibrosis (CF) patients with acute respiratory failure (ARF) Source: Eur Respir J 2003; 22: Suppl. 45, 501s Year: 2003 UIP-like or NSIP pattern in interstitial lung disease patients (ILD), following by ‘connective tissue disease ‘(CTD) Source: Annual Congress 2012 - Diffuse parenchymal lung disease III Year: 2012 Breathing pattern during rest and exercise in patients with cystic fibrosis (CF), pulmonary fibrosis (PF) and COPD before lung transplantation Source: Eur Respir J 2005; 26: Suppl. 49, 685s Year: 2005 Whole lung lavage efficacy in pulmonary alveolar proteinosis (PAP) is influenced by the infusion volume? Source: International Congress 2015 – IIPs: orphan Year: 2015 Benefit of treatment with pirfenidone (PFD) persists over time in patients with idiopathic pulmonary fibrosis (IPF) with limited lung function impairment Source: International Congress 2016 – IPF treatment I Year: 2016 Whole lung lavage therapy (WLL) of pulmonary alveolar proteinosis (PAP): A global survey of current practices and procedures Source: International Congress 2016 – Orphan diseases I Year: 2016 Comparison of survival rate following non-invasive ventilation in chronic obstructive pulmonary disease (COPD) and non-COPD patients Source: Annual Congress 2010 - Noninvasive ventilation in the acute patient: outcome and pathophysiology Year: 2010 Inhaled sargramostim and whole lung lavage (WLL) as therapy of autoimmune pulmonary alveolar proteinosis (aPAP) Source: International Congress 2016 – Orphan diseases I Year: 2016